Skip to main content

Treatment for Colorectal Cancer

Study name: Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)

Description: Researchers at the WL Nugent Cancer Center are conducting a Phase III clinical trial to determine if a higher dose of vitamin D3 in combination with standard chemotherapy and immunotherapy medications possibly improves patient outcomes.

  • Group 1 (investigational treatment): Receive high-dose vitamin D3 in combination with chemotherapy (FOLFOX/FOLFIRI) and immunotherapy (bevacizumab) medications.
  • Group 2 (current standard treatment): Receive regular-dose vitamin D3 in combination with chemotherapy (FOLFOX/FOLFIRI) and immunotherapy (bevacizumab) medications.

Who can participate?

This study is open to men and women age 18 and over who:

  • Have been diagnosed with advanced colorectal cancer
  • Have not yet received treatment for colorectal cancer
  • Do not have MSI-H or dMMR tumors.

What to expect

  • You will meet with your doctor to discuss what is involved in the study and the possible benefits and risks. If you and your doctor agree this clinical trial is right for you, you will be asked to sign a consent form.
  • This is a randomized study, where you will be assigned by chance to one of the treatment sequences listed above. Patients are twice more likely to be included in Group 1 than Group 2.
  • You will periodically complete questionnaires about your condition, side-effects from treatment, etc.
  • Blood samples may be collected before, during, and after treatment for study analysis.


Please talk with your doctor about whether this clinical trial is right for you.